Next Article in Journal
Salicylic Acid Induces Resistance in Rubber Tree against Phytophthora palmivora
Next Article in Special Issue
Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours
Previous Article in Journal
Experimental Model of Human Malignant Mesothelioma in Athymic Mice
Previous Article in Special Issue
Recent Insights into Mucinous Ovarian Carcinoma
Review

Glutathione in Ovarian Cancer: A Double-Edged Sword

by 1,2 and 1,2,*
1
Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisboa, Portugal
2
Unidade de Investigação em Patobiologia Molecular do Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(7), 1882; https://doi.org/10.3390/ijms19071882
Received: 30 May 2018 / Revised: 15 June 2018 / Accepted: 25 June 2018 / Published: 26 June 2018
(This article belongs to the Special Issue Ovarian Cancer: Pathogenesis, Diagnosis, and Treatment)
Glutathione (GSH) has several roles in a cell, such as a reactive oxygen species (ROS) scavenger, an intervenient in xenobiotics metabolism and a reservoir of cysteine. All of these activities are important in the maintenance of normal cells homeostasis but can also constitute an advantage for cancer cells, allowing disease progression and resistance to therapy. Ovarian cancer is the major cause of death from gynaecologic disease and the second most common gynaecologic malignancy worldwide. In over 50 years, the overall survival of patients diagnosed with epithelial ovarian cancer has not changed, regardless of the efforts concerning early detection, radical surgery and new therapeutic approaches. Late diagnosis and resistance to therapy are the main causes of this outcome, and GSH is profoundly associated with chemoresistance to platinum salts, which, together with taxane-based chemotherapy and surgery, are the main therapy strategies in ovarian cancer treatment. Herein, we present some insights into the role of GSH in the poor prognosis of ovarian cancer, and also point out how some strategies underlying the dependence of ovarian cancer cells on GSH can be further used to improve the effectiveness of therapy. View Full-Text
Keywords: ovarian cancer; cancer metabolism; glutathione; cysteine; chemoresistance; platinum based drugs ovarian cancer; cancer metabolism; glutathione; cysteine; chemoresistance; platinum based drugs
Show Figures

Graphical abstract

MDPI and ACS Style

Nunes, S.C.; Serpa, J. Glutathione in Ovarian Cancer: A Double-Edged Sword. Int. J. Mol. Sci. 2018, 19, 1882. https://doi.org/10.3390/ijms19071882

AMA Style

Nunes SC, Serpa J. Glutathione in Ovarian Cancer: A Double-Edged Sword. International Journal of Molecular Sciences. 2018; 19(7):1882. https://doi.org/10.3390/ijms19071882

Chicago/Turabian Style

Nunes, Sofia C., and Jacinta Serpa. 2018. "Glutathione in Ovarian Cancer: A Double-Edged Sword" International Journal of Molecular Sciences 19, no. 7: 1882. https://doi.org/10.3390/ijms19071882

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop